“I am gobsmacked that Lilly is seeking confidential patient medical records to build a case against the very therapies that ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as ...

Eli Lilly will work with RNA-focused Haya Therapeutics to search for new targets to develop drugs for metabolic conditions ...

Our analysis of options history for Eli Lilly LLY revealed 21 unusual trades. Delving into the details, we found 28% of traders were bullish, while 52% showed bearish tendencies. Out of all the ...

Eli Lilly shares jumped to an all-time high on Tuesday ... patients with prediabetes and either obesity or overweight also found that those who received tirzepatide lost 22.9% of their body ...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...

The primary cause for the selloff could be because Eli Lilly (NYSE:LLY ... a treatment for diabetes that was found to have a tremendous impact on obesity. Semaglutide, the active ingredient ...

A 3-year-study of Zepbound and Mounjaro found the GLP-1 drugs can help prevent ... funded by drugmaker Eli Lilly, suggest that taking Zepbound or Mounjaro may reduce the risk of developing ...

Eli Lilly & Co. is asking people who took copies ... and some state inspections have found worrisome practices, the pharmacies say they are following the law and helping Americans get medicines ...

A pair of late-stage trials found that Eli Lilly & Co.’s experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday ...

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...